Tempus, operated by Tempus AI, Inc., is an AI-enabled precision medicine platform built for biopharma R&D teams, clinical trial sponsors, diagnostic researchers, and oncologists. It connects clinical software, real-world multi-omics data, and laboratory infrastructure to address the fragmentation of healthcare data across oncology, cardiology, neurology, and psychiatry.
The platform collects and structures multimodal data, including next-generation sequencing (NGS) molecular data, pathology slides, unstructured clinical notes, and imaging. Researchers query this data through the Tempus Lens agentic platform, while proprietary AI foundation models such as Virchow and PRISM handle computational pathology, and oFM supports multimodal oncology research.
Beyond software, Tempus runs CAP-accredited and CLIA-certified genomic sequencing laboratories, develops companion diagnostics (CDx), and operates a Contract Research Organization (CRO) for oncology clinical trial execution. This pairing of physical lab infrastructure with computational tools distinguishes it from software-only research platforms.
As of Tempus’s May 2026 ASCO announcement, the company reports more than 45 million de-identified patient journeys and over 500 petabytes of molecularly grounded data, connected to over 5,500 hospitals and 8,500 oncologists. Other Tempus materials cite different snapshot figures, so treat all volume statistics as approximate and self-reported.
Pricing
Tempus does not publish pricing, free trials, or subscription tiers. Access to Lens, the multimodal dataset, sequencing services, and CDx or CRO partnerships is negotiated through custom enterprise agreements, with terms varying by data scope, platform embedding, and laboratory partnership needs. Prospective customers must contact Tempus directly to receive a quote.
* Disclaimer: Please note that pricing information may not be up to date. For the most accurate and current pricing details, refer to the official website.
Key Features
-
✓
Tempus Lens for cohort building, trial simulation, and real-world evidence generation
-
✓
Multimodal real-world dataset linking clinical, molecular, and imaging records
-
✓
AI foundation models Virchow, PRISM, and oFM for pathology and oncology research
-
✓
Clinical-grade NGS sequencing across solid tumors, liquid biopsy, and MRD
-
✓
Companion diagnostics co-development supported by FDA-authorized assays
-
✓
Tempus Compass CRO services for complex oncology clinical development
Use Cases
Target Validation and Biomarker Strategy
Biopharma discovery teams query the multimodal dataset to identify genetic targets and assess disease prevalence before entering clinical trials. Pairing clinical outcomes with multi-omic data lets computational models evaluate biomarker prevalence in real-world cohorts.
Clinical Trial Protocol Feasibility
Clinical development teams simulate recruitment parameters using longitudinal patient histories across the Tempus clinical network. This identifies realistic patient pool availability and reduces protocol amendments and feasibility delays.
Companion Diagnostic Co-Development
Drug developers partner with Tempus to co-develop, validate, and commercialize companion diagnostics alongside a targeted therapy. FDA-authorized assay infrastructure such as xT CDx supports faster regulatory workflows and deployment across the clinician network.
External Control Arms for Submissions
Researchers build external comparator arms from de-identified real-world records to contextualize single-arm trial results. This supports efficacy and safety arguments to regulators using real-world mortality and progression endpoints.
Preclinical Drug Screening with Organoids
Translational research teams screen oncology drug candidates against ex vivo tumor-derived organoids linked to patient background data. This evaluates candidate efficacy, combination regimens, and resistance mechanisms before clinical testing.
Strengths & Weaknesses
Strengths
Holds tens of millions of de-identified patient journeys spanning clinical, molecular, and imaging data.
Partnered with 95% of the top 20 pharmaceutical companies and over 250 biopharma organizations.
Operates CLIA-certified, CAP-accredited sequencing labs with FDA-authorized assays such as xT CDx.
Connects to over 5,500 hospitals and 8,500 oncologists, giving research findings a direct path to clinical settings.
Covers the full biopharma lifecycle, from target discovery through CRO operations and companion diagnostics.
Weaknesses
Pricing, subscription tiers, and assay fees are not disclosed anywhere on the public website.
Advanced CRO, data, and diagnostic features require deep reliance on the proprietary Tempus ecosystem.
Abstracting complex clinical and genomic data relies on proprietary AI processes that need ongoing validation across non-standardized EHR systems.
Small biotechs or academic labs with limited budgets may face high financial barriers to enterprise-grade data licensing or full CRO services.
Who Is This For?
Biopharmaceutical R&D teams needing multi-omic and real-world clinical data to de-risk target discovery and biomarker strategy.
Clinical operations and trial sponsors requiring site activation networks, patient recruitment, and specialized CRO services.
Diagnostic and translational researchers needing high-throughput sequencing, multi-omics tools, and organoid models.
Healthcare providers and oncologists who want clinical-grade genomic testing and trial matching tools to guide treatment.
Frequently Asked Questions
How much does Tempus cost?
Tempus does not publish pricing. Access to its platform, lab services, or CRO offerings is negotiated through custom enterprise agreements based on scope and integration needs.
What kind of data does Tempus provide access to?
Tempus reports tens of millions of de-identified patient journeys linking clinical outcomes, genomic sequencing data, pathology imaging, and radiology imaging.
Are Tempus laboratories accredited?
Yes. Tempus operates CLIA-certified, CAP-accredited sequencing laboratories and holds FDA-authorized assays including xT CDx and xR IVD.
Can Tempus help develop a companion diagnostic?
Yes. Tempus offers end-to-end CDx co-development, from biomarker discovery through FDA approval and distribution across its clinician network.
What foundation models does Tempus offer?
Tempus provides Virchow and PRISM for computational pathology, plus oFM for multimodal oncology research.
Does Tempus integrate with existing EHR systems?
Tempus integrates with provider EHR systems to abstract unstructured clinical notes and match patients to trials, though specific named third-party EHR vendors are not listed publicly.
Who typically uses Tempus?
Its primary users are biopharma R&D teams, clinical trial sponsors, diagnostic researchers, and oncologists who need multimodal patient data or sequencing services.
Is there a free trial or self-serve signup?
No. Tempus does not offer a public free plan or self-serve trial; engagement starts with a direct conversation with the Tempus team.
How does Tempus support clinical trial recruitment?
Through its clinical network, Tempus connects thousands of hospitals and oncologists, letting trial sponsors identify and recruit patients for biomarker-driven studies.
What sets Tempus apart from other real-world data providers?
Tempus combines a large multimodal patient dataset with its own accredited sequencing labs, CDx development, CRO services, and patient-derived organoid modeling under one platform.
Tempus integrates directly with provider EHR systems to abstract unstructured clinical notes and match patients to trials, and the Tempus Lens platform interfaces with internal biopharma data stacks and computational workflows. It also connects into thousands of healthcare sites for lab test orders, results reporting, and trial recruitment. No specific named third-party software integrations, such as individual commercial EHR vendors or API connectors, are publicly listed.